红日药业 reported revenue of ¥2.19B for the period ended 2026-06-30, -21.7% year on year. Net income was ¥0.08B, a 3.8% net margin on a 57.0% gross margin. The largest revenue line is 药品 at 76% of the total. Free cash flow for the period was ¥0.25B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.19B | -21.7% |
| Gross profit | ¥1.25B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.08B | -2.0% |
| Gross margin | 57.0% | Net margin 3.8% |
| Revenue Q/Q | -6.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品 | ¥1.67B | 76.4% |
| 原辅料 | ¥0.24B | 11.0% |
| 医疗器械 | ¥0.12B | 5.4% |
| 智慧供应链 | ¥0.11B | 5.1% |
| 其他 | ¥0.04B | 2.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.94B | 43.0% |
| R&D | ¥0.09B | 3.9% |
| SG&A | ¥0.98B | 44.7% |
| Tax & other | ¥0.02B | 1.1% |
| Item | Amount |
|---|---|
| Total assets | ¥10.33B |
| Total liabilities | ¥1.65B |
| Shareholders' equity | ¥8.68B |
| Equity / assets | 84.1% |
| Operating cash flow | ¥0.27B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.25B |
| Cash conversion (OCF / net income) | 432% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST华谊 ・ 阳普医疗 ・ 宝通科技 ・ 金龙机电 ・ 钢研高纳 ・ 中科电气 ・ 超图软件 ・ 新宙邦 ・ 上海凯宝 ・ 九洲集团 ・ 回天新材 ・ 朗科科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies